Position of TIPS (transjugular intrahepatic portosystemic shunt) in the treatment of the refractory ascitis;Place du TIPS dans le traitement de l'ascite réfractaire

Gastroenterologie Clinique et Biologique

Volumn 31, Issue 3, 2007, Pages 341-346

  Péron, Jean Marie ^a   Bureau, Christophe ^a   Vinel, Jean Pierre ^a  

^a CHU PURPAN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BILIRUBIN; FUROSEMIDE; SPIRONOLACTONE; VASOPRESSIN;

ASCITES; BRAIN DISEASE; CLINICAL EFFECTIVENESS; HEALTH CARE COST; HORMONE RELEASE; HUMAN; HYPERBILIRUBINEMIA; INTERMETHOD COMPARISON; LIVER CIRRHOSIS; LIVER FAILURE; LIVER TRANSPLANTATION; MORTALITY; NUTRITIONAL ASSESSMENT; PARACENTESIS; PORTOSYSTEMIC ANASTOMOSIS; PROGNOSIS; QUALITY OF LIFE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SURGICAL TECHNIQUE; SURVIVAL; SYMPATHETIC NERVE; TREATMENT CONTRAINDICATION; TREATMENT OUTCOME;

EID: 34147165486     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0399-8320(07)89387-0     Document Type: Review

References (48)

1. Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodes J. Peripheral arterial vasodilation hypothesis : a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988;8:1151-7.
2. Pariente A. Comment traiter une première poussée d'ascite ? Gastroenterol Clin Biol 2004 ;28 Spec No 2:B256-65.
3. Guardiola J, Baliellas C, Xiol X, Fernandez Esparrach G, Gines P, Ventura P, Vazquez S. External validation of a prognostic model for predicting survival of cirrhotic patients with refractory ascites. Am J Gastroenterol 2002;97:2374-8.
4. Arroyo V, Gines P, Gerbes AL, Dudley FJ, Gentilini P, Laffi G, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology 1996;23:164-76.
5. Pomier-Layrargues G. Traitement de l'ascie réfractaire. Gastroenterol Clin Biol 2004;28 Spec No 2:B266-9.
6. Runyon BA. Paracentesis of ascitic fluid. A safe procedure. Arch Intern Med 1986;146:2259-61.
7. Gines A, Fernandez-Esparrach G, Monescillo A, Villa C, Domenech E, Abecasis R, et al. Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology 1996;111:1002-10.
8. Ruiz-del-Arbol L, Monescillo A, Jimenez W, Garcia-Plaza A, Arroyo V, Rodes J. Paracentesis-induced circulatory dysfunction : mechanism and effect on hepatic hemodynamics in cirrhosis. Gastroenterology 1997;113:579-86.
9. Gines P, Tito L, Arroyo V, Planas R, Panes J, Viver J, et al. Randomized comparative study of therapeutic paracentesis with or without intravenous albumin in cirrhosis. Gastroenterology 1988; 94:1493-502.
10. Garcia-Compean D, Zacarias Villareal J, Bahena Cuevas H, Garcia Cantu DA, Estrella M, Garza Tamez E, et al. Total therapeutic paracentesis with and without intravenous albumin in the treatment of cirrhotic tense ascites : a randomized controlled trial. Liver 1993;13:233-8.
11. Christidis C, Mal F, Ramos J, Senejoux A, Callard P, Navarro R et al. Worsening of hepatic dysfunction as a consequence of repeated hydroxyethylstarch infusions. J Hepatol 2001 ;35 :726-32.
12. Laxenaire MC, Charpentier C, Feldman L. Réactions anaphylactoïdes aux substituts colloïdaux du plasma : incidence, facteurs de risque, mécanismes. Enquête prospective multicentrique française. Ann Fr Anesth Reanim 1994;13:301-10.
13. Planas R, Gines P, Arroyo V, Llach J, Panes J, Vargas V, et al. Dextran-70 versus albumin as plasma expanders in cirrhotic patients with tense ascites treated with total paracentesis. Results of a randomized study. Gastroenterology 1990;99:1736-44.
14. Salerno F, Badalamenti S, Lorenzano E, Moser P, Incerti P. Randomized comparative study of hemaccel vs. albumin infusion after total paracentesis in cirrhotic patients with refractory ascites. Hepatology 1991;13:707-13.
15. Fassio E, Terg R, Landeira G, Abecasis R, Salemne M, Podesta A, Rodriguez P, Levi D, Kravetz D. Paracentesis with Dextran 70 vs. paracentesis with albumin in cirrhosis with tense ascites. Results of a randomized study. J Hepatol 1992;14:310-6.
16. Gines A, Fernandez-Esparrach G, Monescillo A, Vila C, Domenech E, Abecasis R, et al. Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology 1996;111:1002-10.
17. Altman C, Bernard B, Roulot D, Vitte RL, Ink O. Randomized comparative multicenter study of hydroxyethyl starch versus albumin as a plasma expander in cirrhotic patients with tense ascites treated with paracentesis. Eur J Gastroenterol Hepatol 1998 ;10 :5-10.
18. Sola-Vera J, Minana J, Ricart E, Planella M, Gonzalez B, Torras X, et al. Randomized trial comparing albumin and saline in the prevention of paracentesis-induced circulatory dysfunction in cirrhotic patients with ascites. Hepatology 2003;37:1147-53.
19. Moreau R, Valla DC, Durand-Zaleski I, Bronowicki JP, Durand F, Chaput JC, et al. Comparison of outcome in patients with cirrhosis and ascites following treatment with albumin or a synthetic colloid: a randomised controlled pilot trail. Liver Int 2006;26:46-54.
20. Boyer TD. Transjugular intrahepatic portosystemic shunt: current status. Gastroenterology 2003 ;124:1700-10.
21. Rector WG Jr . Portal hypertension: a permissive factor only in the development of ascites and variceal bleeding. Liver 1986;6:221-6.
22. Morali GA, Sniderman KW, Deitel KM, Tobe S, Witt-Sullivan H, Simon M, et al. Is sinusoidal portal hypertension a necessary factor for the development of hepatic ascites? J Hepatol 1992;16:249-50.
23. Bureau C, Péron JM, Alric L, Morales J, Sanchez J, Barange K, et al. "A La Carte" treatment of portal hypertension: Adapting medical therapy to hemodynamic response for the prevention of bleeding. Hepatology 2002;36:1361-6.
24. Bureau C, Garcia-Pagan JC, Otal P, Pomier-Layrargues G, Chabbert V, Cortez C, et al. Improved clinical outcome using polytetrafluoroethylene-coated stents for TIPS: results of a randomized study. Gastroenterology 2004;126:469-75.
25. Angermayr B, Cejna M, Koenig F, Karnel F, Hackl F, Gangl A, Peck-Radosavljevic M. Vienna TIPS Study Group. Survival in patients undergoing transjugular intrahepatic portosystemic shunt: ePTFE-covered stentgrafts versus bare stents. Hepatology 2003;38:1043-50.
26. Franco D, Vons C, Traynor O, de Smadja C. Should portosystemic shunts be considered in the treatment of intractable ascites in cirrhosis ? Arch Surg 1988;123:897-91.
27. Somberg KA, Lake JR, Tomlanovich SJ, LaBerge JM, Feldstein V, Bass NM. Transjugular intrahepatic portosystemic shunts for refractory ascites: assessment of clinical and hormonal response and renal function. Hepatology 1995;21:709-16.
28. Quiroga J, Sangro B, Nunez M, Bilbao I, Longo J, Garcia-Villarreal L, et al. Transjugular intrahepatic portal-systemic shunt in the treatment of refractory ascites: effect on clinical, renal, humoral, and hemodynamic parameters. Hepatology 1995;21:986-94.
29. Williams DB, Waugh R, Selby W. Transjugular intrahepatic portosystemic shunt (TIPS) for the treatment of refractory ascites. Aust N Z J Med 1998;28:620-6.
30. Deschenes M, Dufresne MP, Bui B, Fenyves D, Spahr L, Roy L, et al. Predictors of clinical response to transjugular intrahepatic portosystemic shunt (TIPS) in cirrhotic patients with refractory ascites. Am J Gastroenterol 1999;94:1361-5.
31. Michl P, Gulberg V, Bilzer M, Waggershauser T, Reiser M, Gerbes AL. Transjugular intrahepatic portosystemic shunt for cirrhosis and ascites: Effects in patients with organic or functional renal failure. Scand J Gastroenterol 2000;35:654-8.
32. Péron JM, Barange K, Otal P, Rousseau H, Payen JL, Pascal JP, et al. Transjugular intrahepatic portosystemic shunts in the treatment of refractory ascites: results in 48 consecutive patients. J Vasc Interv Radiol 2000;11:1211-6.
33. Lebrec D, Giuily N, Hadengue A, Vilgrain V, Moreau R, Poynard T, et al. Transjugular intrahepatic portosystemic shunts: comparison with paracentesis in patients with cirrhosis and refractory ascites: a randomized trial. French Group of Clinicians and a Group of Biologists. J Hepatol 1996;25:135-44.
34. Rössle M, Ochs A, Gulberg V, Siegerstetter V, Holl J, Deibert P, et al. A comparison of paracentesis and transjugular intrahepatic portosystemic shunting in patients with ascites. N Engl J Med 2000;342:1701-7.
35. Gines P, Uriz J, Calahorra B, Garcia-Tsao G, Kamath PS, Del Arbol LR, et al. Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. Gastroenterology 2002;123:1839-47.
36. Sanyal AJ, Genning C, Reddy KR, Wong F, Kowdley KV, Benner K, McCashland T; North American Study for the Treatment of Refractory Ascites Group. The North American Study for the Treatment of Refractory Ascites. Gastroenterology 2003;124:634-41.
37. Salerno F, Merli M, Riggio O, Cazzaniga M, Valeriano V, Pozzi M, et al. Randomized controlled study of TIPS versus paracentesis plus albumin in cirrhosis with severe ascites. Hepatology 2004;40:629-35.
38. Deltenre P, Mathurin P, Dharancy S, Moreau R, Bulois P, Henrion J, et al. Transjugular intrahepatic portosystemic shunt in refractory ascites: a meta-analysis. Liver Int 2005;25:349-56.
39. Albillos A, Banares R, Gonzalez M, Catalina MV, Molinero LM. A meta-analysis of transjugular intrahepatic portosystemic shunt versus paracentesis for refractory ascites. J Hepatol 2005;43:990-6.
40. D'Amico G, Luca A, Morabito A, Miraglia R, D'Amico M. Uncovered transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis. Gastroenterology 2005;129:1282-93.
41. Gerbes AL, Gulberg V. Benefit of TIPS for patients with refractory or recidivant ascites: serum bilirubin may make the difference. Hepatology 2005;41:217.
42. Rajan DK, Haskal ZJ, Clark TW. Serum bilirubin and early mortality after transjugular intrahepatic portosystemic shunts: results of a multivariate analysis. J Vasc Interv Radiol 2002;13:155-61.
43. Gulberg V, Liss I, Bilzer M, Waggershauser T, Reiser M, Gerbes AL. Improved quality of life in patients with refractory or recidivant ascites after insertion of transjugular intrahepatic portosystemic shunts. Digestion 2002;66:127-30.
44. Zhuang ZW, Teng GJ, Jeffery RF, Gemery JM, Janne d'Othee B, Bettmann MA. Long-term results and quality of life in patients treated with transjugular intrahepatic portosystemic shunts. AJR Am J Roentgenol 2002;179:1597-603.
45. Nazarian GK, Ferral H, Bjarnason H, Castaneda-Zuniga WR, Rank JM, Bernadas CA, Hunter DW. Effect of transjugular intrahepatic portosystemic shunt on quality of life. AJR Am J Roentgenol 1996;167:963-9.
46. Plauth M, Schutz T, Buckendahl DP, Kreymann G, Pirlich M, Grungreiff S,et al. Weight gain after transjugular intrahepatic portosystemic shunt is associated with improvement in body composition in malnourished patients with cirrhosis and hypermetabolism. J Hepatol 2004;40:228-33.
47. Allard JP, Chau J, Sandokji K, Blendis LM, Wong F. Effects of ascites resolution after successful TIPS on nutrition in cirrhotic patients with refractory ascites. Am J Gastroenterol 2001;96:2442-7.
48. Rosemurgy AS 2nd, Bloomston M, Zervos EE, Goode SE, Pencev D, Zweibel B, Black TJ. Transjugular intrahepatic portosystemic shunt versus H-graft portacaval shunt in the management of bleeding varices: a cost-benefit analysis. Surgery 1997;122:794-9